<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421210</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00089183</org_study_id>
    <secondary_id>1R01DA038442</secondary_id>
    <nct_id>NCT03421210</nct_id>
  </id_info>
  <brief_title>Effects of Smoking Environments on Brain Reactivity</brief_title>
  <acronym>CameraCue3</acronym>
  <official_title>Effects of Smoking Environments on Brain Reactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate correlations between brain reactivity (as assessed via&#xD;
      functional magnetic resonance imaging (fMRI) following 24-h abstinence) and the amount of&#xD;
      smoking in a specific location. The investigators will use ecological momentary assessment&#xD;
      (EMA) to ask smokers to rate their exposure to, and smoking in, specific personal smoking&#xD;
      environment cues (PSEs) over the course of 2 weeks before quitting smoking and 2 weeks after&#xD;
      quitting smoking. The investigators propose to identify 48 regular cigarette smokers who will&#xD;
      complete 8 visits (1 screening visit, 1 training visit, 1 camera turn-in visit, 1 fMRI&#xD;
      session and 4 post-quit medication check sessions). Multiple methods will be used to test&#xD;
      hypotheses about brain functioning during cue-reactivity (CR). The investigators will examine&#xD;
      correlation between brain responses to smoking environments (minus non-smoking environments)&#xD;
      and smoking cessation outcomes (i.e. days to lapse, days to relapse). Our EMA+Global&#xD;
      Positioning System (GPS) analysis will primarily focus on locations where smokers smoke&#xD;
      before and after quitting smoking. The investigators will evaluate whether EMA-assessed&#xD;
      smoking intensity values are correlated with brain responses to these personal smoking&#xD;
      environments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signal Change in Functional Magnetic Resonance Imaging (fMRI) Contrast of Parameter Estimate (COPE) Between Personal Environment Pictures Relative to Non-Personal Environment Pictures</measure>
    <time_frame>4 weeks</time_frame>
    <description>Using fMRI the investigators examined brain function during cue-reactivity. During the scan, participants viewed pictures of personal and non-personal environments.&#xD;
Contrast of parameter estimate (COPE) values for the difference between personal smoking environment pictures and non-personal smoking environment pictures were extracted from anatomically defined brain regions using FSL's featquery for analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Quit Craving as Measured by (Ecological Momentary Assessment) EMA Questionnaire</measure>
    <time_frame>2 weeks after quitting smoking</time_frame>
    <description>EMA will be used to evaluate craving daily for 2 weeks after quitting. Subjects will rate their craving on a single item (How strong is your current urge to smoke?) using a scale from 1 &quot;very slightly or not at all&quot; to 5 &quot;extremely&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Relapse</measure>
    <time_frame>Weeks 1, 3, 6, and 10 weeks after quitting.</time_frame>
    <description>Relapse defined as 7 consecutive days smoking at least 1 cigarette per day. Individuals lost to contact are presumed to have relapsed following their last visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Nicotine Replacement Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
    <arm_group_label>Nicotine Replacement Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. generally healthy [(i.e. ambulatory, not currently sick)]&#xD;
&#xD;
          2. between the ages of 18 and 65&#xD;
&#xD;
          3. smoking of at least 5 cig/day of a brand delivering â‰¥ 0.5 mg nicotine (FTC method) for&#xD;
             &gt; 1 year&#xD;
&#xD;
          4. an expired carbon monoxide (CO) concentration of at least 10 ppm (to confirm&#xD;
             inhalation) or urinary cotinine &gt;1000 ng/mL (NicAlert = 6).&#xD;
&#xD;
          5. interest in quitting smoking within the timeframe of the experiment.&#xD;
&#xD;
          6. ability to identify 4 personal smoking and 4 personal non-smoking places.&#xD;
&#xD;
          7. right handed as measured by a three-item scale used in our laboratory&#xD;
&#xD;
          8. own a smartphone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. immediate or no desire to quit smoking;&#xD;
&#xD;
          2. inability to attend all required experimental sessions;&#xD;
&#xD;
          3. use of other tobacco products or e-cigarettes more than 9 days in the past 30 days;&#xD;
&#xD;
          4. current alcohol or drug abuse;&#xD;
&#xD;
          5. positive toxicology screen for any of the following drugs: cocaine, opiates,&#xD;
             methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and&#xD;
             Phencyclidine(PCP)&#xD;
&#xD;
               1. marijuana will be tested for but will not be exclusionary;&#xD;
&#xD;
               2. participants with valid prescriptions for opiates, benzodiazepines, barbiturates,&#xD;
                  amphetamines or methadone will not be excluded;&#xD;
&#xD;
               3. participants failing the toxicology screen will be allowed to re-screen once;&#xD;
&#xD;
          6. current use of nicotine replacement therapy or other smoking cessation treatment;&#xD;
&#xD;
          7. screening systolic BP greater than 140 (participants failing for blood pressure will&#xD;
             be allowed to rescreen once)&#xD;
&#xD;
          8. screening diastolic BP greater than 90 (participants failing for blood pressure will&#xD;
             be allowed to rescreen once)&#xD;
&#xD;
          9. screening heart rate greater than 100 (participants failing for heart rate will be&#xD;
             allowed to rescreen once)&#xD;
&#xD;
         10. presence of conditions contraindicated for nicotine replacement therapy (e.g., skin&#xD;
             allergies)&#xD;
&#xD;
         11. report of significant health problems including but not restricted to (e.g. chronic&#xD;
             hypertension, emphysema, seizure disorder, history of significant heart problems,&#xD;
             heart disease, heart attack in the past 90 days, irregular heartbeat)&#xD;
&#xD;
         12. medical condition that may contraindicate participation in the opinion of the&#xD;
             investigator and study physician.&#xD;
&#xD;
         13. current major psychiatric disease such as schizophrenia or schizoaffective disorder&#xD;
&#xD;
         14. currently pregnant, breast feeding or likely to become pregnant;&#xD;
&#xD;
         15. a quit attempt resulting in greater than 3 days of abstinence in the past 30 days&#xD;
&#xD;
         16. presence of conditions that would make MRI unsafe (e.g., pacemaker)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis J McClernon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03421210/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Replacement Therapy</title>
          <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.&#xD;
Nicotine patch: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Functional Magnetic Resonance Imaging (fMRI)</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who completed the study. Those with excessive head motion or artifacts identified during QA checks were not included in analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Replacement Therapy</title>
          <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.&#xD;
Nicotine patch: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Signal Change in Functional Magnetic Resonance Imaging (fMRI) Contrast of Parameter Estimate (COPE) Between Personal Environment Pictures Relative to Non-Personal Environment Pictures</title>
        <description>Using fMRI the investigators examined brain function during cue-reactivity. During the scan, participants viewed pictures of personal and non-personal environments.&#xD;
Contrast of parameter estimate (COPE) values for the difference between personal smoking environment pictures and non-personal smoking environment pictures were extracted from anatomically defined brain regions using FSL's featquery for analysis.</description>
        <time_frame>4 weeks</time_frame>
        <population>Subjects who completed the study. Those with excessive head motion or artifacts identified during QA checks were not included in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Replacement Therapy</title>
            <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.&#xD;
Nicotine patch: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Signal Change in Functional Magnetic Resonance Imaging (fMRI) Contrast of Parameter Estimate (COPE) Between Personal Environment Pictures Relative to Non-Personal Environment Pictures</title>
          <description>Using fMRI the investigators examined brain function during cue-reactivity. During the scan, participants viewed pictures of personal and non-personal environments.&#xD;
Contrast of parameter estimate (COPE) values for the difference between personal smoking environment pictures and non-personal smoking environment pictures were extracted from anatomically defined brain regions using FSL's featquery for analysis.</description>
          <population>Subjects who completed the study. Those with excessive head motion or artifacts identified during QA checks were not included in analyses.</population>
          <units>contrast of parameter estimate (COPE)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0598" spread="0.09454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Differences in brain activation in response to personal smoking versus standard smoking cues were examined.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Quit Craving as Measured by (Ecological Momentary Assessment) EMA Questionnaire</title>
        <description>EMA will be used to evaluate craving daily for 2 weeks after quitting. Subjects will rate their craving on a single item (How strong is your current urge to smoke?) using a scale from 1 &quot;very slightly or not at all&quot; to 5 &quot;extremely&quot;.</description>
        <time_frame>2 weeks after quitting smoking</time_frame>
        <population>All participants with post-quit EMA data.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Replacement Therapy</title>
            <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.&#xD;
Nicotine patch: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Quit Craving as Measured by (Ecological Momentary Assessment) EMA Questionnaire</title>
          <description>EMA will be used to evaluate craving daily for 2 weeks after quitting. Subjects will rate their craving on a single item (How strong is your current urge to smoke?) using a scale from 1 &quot;very slightly or not at all&quot; to 5 &quot;extremely&quot;.</description>
          <population>All participants with post-quit EMA data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Relapse</title>
        <description>Relapse defined as 7 consecutive days smoking at least 1 cigarette per day. Individuals lost to contact are presumed to have relapsed following their last visit.</description>
        <time_frame>Weeks 1, 3, 6, and 10 weeks after quitting.</time_frame>
        <population>42 subjects entered the quit phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Replacement Therapy</title>
            <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.&#xD;
Nicotine patch: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Relapse</title>
          <description>Relapse defined as 7 consecutive days smoking at least 1 cigarette per day. Individuals lost to contact are presumed to have relapsed following their last visit.</description>
          <population>42 subjects entered the quit phase of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks after quitting smoking</time_frame>
      <desc>Adverse events were typically identified during the administration of the Side Effects form and deemed to require followup. Other events were identified from physiological measures or by spontaneous reports during assessments.Participant's fMRI session was followed by a quit day and 10 weeks of patch use (this period included 4 follow up visits). 42 participants were scanned, 32 had usable fMRI data, 35 participants completed the entire study (all 10 weeks post quit date)</desc>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Replacement Therapy</title>
          <description>Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.&#xD;
Nicotine patch: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Mouth/Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Elevated CESD score</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nasal congestion/ sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash at Patch site</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Itching/burning at patch site</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dizzyness upon standing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Feeling Faint</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hand Numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony DeVito, MD</name_or_title>
      <organization>Duke University</organization>
      <phone>919-684-1377</phone>
      <email>anthony.devito@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

